|
GB201005005D0
|
|
New vaccine
|
|
WO2011106929A1
|
|
Inhibitors of hepatitis c virus ns5b polymerase
|
|
WO2010082050A1
|
|
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
|
GB0916646D0
|
|
New method of calculating areas
|
|
GB0916608D0
|
|
Therapeutic compounds
|
|
GB0916308D0
|
|
Therapeutic compounds
|
|
WO2010018136A1
|
|
Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
|
|
WO2010013037A1
|
|
1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists
|
|
GB0906026D0
|
|
Therapeutic compounds
|
|
GB0900914D0
|
|
Antiviral agents
|
|
GB0900712D0
|
|
Therapeutic compounds
|
|
GB0900484D0
|
|
Therapeutic agent
|
|
GB0822107D0
|
|
Method of generating diversity in polynucleotide sequences
|
|
GB0821817D0
|
|
Therapeutic compounds
|
|
WO2009042053A2
|
|
Neuromedin u receptor agonists and uses thereof
|
|
GB0816707D0
|
|
Therapeutic compounds
|
|
GB0815968D0
|
|
Antiviral agents
|
|
GB0815700D0
|
|
Therapeutic compounds
|
|
GB0814762D0
|
|
Antiviral agents
|
|
CA2699891A1
|
|
Macrocyclic compounds as antiviral agents
|
